Study wrapper · #469
Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.
Editor's note
This meta-analysis reconstructed individual-participant data from four randomised trials (4,149 adults with overweight or obesity and heart failure with mildly reduced or preserved ejection fraction) to estimate how quickly incretin-based therapies, specifically semaglutide and tirzepatide, separate from placebo. Researchers reported a reduction in worsening heart-failure or cardiovascular-death events (hazard ratio 0.59) with low risk of bias and moderate-to-high certainty by GRADE, and a nominal time to first statistical significance of about four months, sustained from roughly six months onward. Because this pools two distinct agents in a specific obesity-related HFpEF/HFmrEF population, the finding should be read at the class level rather than as agent-specific evidence, and the reconstructed-IPD method carries assumptions. Still, the consistency and event reduction make this among the stronger signals for semaglutide and tirzepatide in this cardiac population.
Plain-language abstract
This analysis combined four randomised trials with 4,149 adults who had obesity or overweight and a form of heart failure with a relatively preserved pumping function. The researchers wanted to know how soon the benefits of incretin medicines, semaglutide and tirzepatide, appear. Compared with dummy treatment, these drugs were linked to fewer episodes of worsening heart failure or heart-related death, and the benefit became statistically clear at around four to six months and held afterward. The quality of evidence was rated moderate to high. Because the study grouped two different drugs together in a specific patient group, the results describe the drug class overall rather than what each drug does alone, but the signal was consistent.